NEW YORK, Aug. 3, 2017 /PRNewswire/ --SummaryAttention deficit hyperactivity disorder (ADHD) is a group of behavioral symptoms that include inattentiveness, hyperactivity and impulsiveness, withsymptoms including disorganized work habits, procrastination and inability to sustain attention on tasks or activities. There are a total of 61 products in development for this indication, by 40 companies and five academic institutions. Key companies operating in this pipeline space include NLS Pharma Group and Shire.Read the full report: http://www.reportlinker.com/p05043172/Neuropsychiatric-Disorder-Cluster-Drug-Development-Pipeline-Review.htmlDepression is a mood disorder that causes a persistent feeling of sadness and loss of interest. Signs and symptoms include sleep disturbances, including insomnia or sleeping too much, changes in appetite, anxiety, agitation or restlessness and physical problems, such as back pain or headaches. There are a total of 191 products in development for this indication, by 112 companies and 20 academic institutions. Key companies operating in this pipeline space include Johnson & Johnson, Sumitomo Dainippon Pharma, Luye Pharma Group, Otsuka Holdings and Vanderbilt University.Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. There are a total of 134 products in development for this indication, by 85 companies and nine academic institutions. Key companies operating in this pipeline space include Omeros Corp, Suven Life Sciences, Heptares Therapeutics, Merck & Co, Sumitomo Dainippon Pharma and Vanderbilt University.Finally, Tourette syndrome is a neurological disorder characterized by repetitive, stereotyped, involuntary movements and vocalizations called tics. Symptoms include eye blinking and other eye movements, facial grimacing, shoulder shrugging, and head or shoulder jerking. There are a total of 11 products in development for this indication, by nine companies and one academic institution. Key companies operating in this pipeline space include Catalyst Pharmaceuticals, who are fielding two pipeline products.Across all four of these indications, transporters and receptors of neurotransmitters such as dopamine and serotonin are the most common targets, closely reflecting the current treatment landscape of these diseases.The report " Neuropsychiatric Disorder Cluster Drug Development Pipeline Review, 2017", provides an overview of the pipeline landscape for neuropsychiatric disorders. The report provides comprehensive information on the therapeutics under development and key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD), Depression, Schizophrenia, and Tourette syndrome, and features dormant and discontinued projects.Scope- Which companies are the most active within the pipeline for genetic neuropsychiatric disorder therapeutics?- Which pharmaceutical approaches are the most prominent at each stage of the pipeline and within each indication?- To what extent do universities and institutions play a role within this pipeline, compared to pharmaceutical companies?- What are the most important R&D milestones and data publications to have happened in the field of genetic neuropsychiatric disorders?Reasons to buy- Understand the overall pipeline, with an at-a-glance overview of all products in therapeutic development for each indication- Assess the products in development in granular detail, with an up-to-date overview of each individual pipeline program in each indication, and a comprehensive picture of recent updates and milestones for each- Analyze the companies, institutions and universities currently operating in the pipeline, and the products being fielded by each of theseRead the full report: http://www.reportlinker.com/p05043172/Neuropsychiatric-Disorder-Cluster-Drug-Development-Pipeline-Review.htmlAbout Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.http://www.reportlinker.com__________________________Contact Clare: [email protected]US: (339)-368-6001Intl: +1 339-368-6001
View original content:http://www.prnewswire.com/news-releases/neuropsychiatric-disorder-cluster-drug-development-pipeline-review-2017-300499514.html
SOURCE Reportlinker
